Skip to main content

Table 2 Markers of ovarian reserve (serum hormones, ovarian volume, and antral follicular count) at baseline and after 6 months of therapy in the cyclophosphamide (CYC) and mycophenolate mofetil (MMF) groups

From: Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study

Parameter*

CYC (n = 25)

MMF (n = 25)

Between-group p value (baseline)

Between-group p value (6 months)

Baseline

6 months

p value

Baseline

6 months

p value

LH (IU/ml)

5.8 ± 3.6

17.6 ± 38.4

0.13

9.4 ± 7.7

8.3 ± 5.6

0.55

0.065

0.55

FSH (IU/ml)

5.2 ± 3.4

25.1 ± 46.0

0.03

4.8 ± 1.8

6.1 ± 3.1

0.07

0.938

0.36

E2 (pg/ml)

80.2 ± 57.6

56.1 ± 52.3

0.13

89.6 ± 67.3

113.0 ± 73.3

0.25

0.749

< 0.001

AMH (ng/ml)

5.7 ± 6.7

1.2 ± 1.7

0.002

6.3 ± 3.9

5.8 ± 5.6

0.71

0.061

< 0.001

Inhibin B (pg/ml)

56.1 ± 21.9

16.5 ± 18.0

< 0.001

53.1 ± 24.7

82.9 ± 37.7

0.002

0.547

< 0.001

Ovarian volume (cm3)

29.3 ± 15.8

17.9 ± 13.7

0.005

25.7 ± 20.4

26.1 ± 11.1

0.92

0.49

0.02

Antral follicular count

6.4 ± 2.4

5.5 ± 4.2

0.32

6.7 ± 2.5

8.0 ± 3.0

0.07

0.74

0.02

  1. LH luteinizing hormone, FSH follicle-stimulating hormone, E2 estradiol, AMH anti-Mullerian hormone, CYC cyclophosphamide, MMF mycophenolate mofetil *Reported as mean ± SD